Quantcast

Latest spinal cord compression Stories

2013-10-09 12:54:33

More than 95 percent of advanced prostate cancer patients receive multiple radiation treatments for pain control, despite evidence pointing to equal benefit from single treatments For cancer patients dealing with the pain of tumors that have spread to their bones, doctors typically recommend radiation as a palliative therapy. But as in many areas of medicine, more of this treatment isn't actually better. Medical evidence over the past decade has demonstrated that patients with terminal...

2011-12-22 06:21:33

(Ivanhoe Newswire) — Spinal degeneration is an unavoidable part of aging, and it can lead to spinal cord compression causing problems with dexterity, numbness in the hands, ability to walk, and potential bladder and bowel function. According to this study, patients with spinal cord compressions also had changes in the motor cortex of the brain. The study involved 11 healthy controls and 24 patients with reversible spinal cord compression. "When patients undergo surgery for spinal...

2011-12-16 12:21:08

Spinal degeneration is an unavoidable part of aging. For some, it leads to compression of the spinal cord which can cause problems with dexterity, numbness in the hands, the ability to walk, and in some cases, bladder and bowel function. Now, new research from The University of Western Ontario looks beyond the spinal cord injury in these patients to better understand what is happening in the brain. Researchers Robert Bartha, Dr. Neil Duggal and Izabela Kowalczyk found patients with spinal...

2011-07-15 06:01:00

THOUSAND OAKS, Calif., July 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. This approval of XGEVA applies to all 27 European Union (EU) member states. The EC also granted XGEVA...

2011-02-18 12:16:04

The American Society for Radiation Oncology (ASTRO) Clinical Affairs and Quality Committee has developed a guideline for the use of radiation therapy in treating bone metastases. The guideline will be published in the International Journal of Radiation Oncology"¢Biology"¢Physics, an official journal of ASTRO. Bone metastases are caused when a malignant tumor spreads to the bone. They can lead to debilitating effects including pain, fractures and paralysis due to spinal cord...

2010-04-27 12:53:00

NEW YORK, April 27 /PRNewswire-FirstCall/ -- Radiosurgical approaches to cancer treatment are showing promise in the treatment of lung, liver, and spinal tumors, according to four leading clinical experts who presented at a symposium in New York earlier this month. New approaches to image-guidance and motion management are making it possible to successfully target tumors that are typically hard to reach with a radiosurgical technique doctors call stereotactic body radiotherapy (SBRT)....

2009-09-22 05:28:00

THOUSAND OAKS, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. These results were presented today during the Presidential Session at the 2009 ECCO 15 - ESMO 34 European...

2009-09-21 04:16:00

THOUSAND OAKS, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European...

2009-08-03 16:03:00

THOUSAND OAKS, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced positive top-line results from a pivotal Phase 3 head-to-head trial evaluating denosumab administered subcutaneously versus Zometa((R)) (zoledronic acid) administered as an intravenous (IV) infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. For the primary endpoint, patients treated...

2009-07-07 16:29:00

THOUSAND OAKS, Calif., July 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,049 patients with advanced breast cancer met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. Superiority was demonstrated for both delaying the time to the first on-study Skeletal Related Events (SREs)(fracture,...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related